RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL • US7665597024

36.64 USD
+0.92 (+2.58%)
At close: Feb 19, 2026
36.64 USD
0 (0%)
After Hours: 2/19/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

RIGL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! This makes RIGL very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • RIGL had positive earnings in the past year.
  • RIGL had a positive operating cash flow in the past year.
  • RIGL had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • RIGL has a better Return On Assets (46.72%) than 99.42% of its industry peers.
  • RIGL has a better Return On Equity (96.34%) than 99.42% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 40.17%, RIGL belongs to the top of the industry, outperforming 96.93% of the companies in the same industry.
  • The Operating Margin of RIGL (42.17%) is better than 98.85% of its industry peers.
  • The Gross Margin of RIGL (93.10%) is better than 93.86% of its industry peers.
  • RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
  • RIGL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RIGL has less shares outstanding
  • RIGL has a better debt/assets ratio than last year.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • RIGL has an Altman-Z score of -0.88. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.88, RIGL is in line with its industry, outperforming 56.62% of the companies in the same industry.
  • The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RIGL (0.88) is better than 93.67% of its industry peers.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RIGL (0.25) is worse than 66.03% of its industry peers.
  • Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -0.88
ROIC/WACC7.12
WACC8.91%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
  • RIGL has a Current ratio of 2.28. This is in the lower half of the industry: RIGL underperforms 72.94% of its industry peers.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a worse Quick ratio (2.14) than 72.36% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 4307.14% over the past year.
  • RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.13%.
  • The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%

3.2 Future

  • Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 38.70% on average per year.
  • Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 15.91% on average per year.
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y38.7%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.91%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.94, which indicates a rather cheap valuation of RIGL.
  • RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.04% of the companies in the same industry.
  • RIGL is valuated cheaply when we compare the Price/Earnings ratio to 27.09, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 9.48, which indicates a very decent valuation of RIGL.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 97.89% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (27.98), we can say RIGL is valued rather cheaply.
Industry RankSector Rank
PE 5.94
Fwd PE 9.48
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 99.23% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 98.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.76
EV/EBITDA 4.11
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • RIGL's earnings are expected to grow with 73.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.8%
EPS Next 3Y73.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (2/19/2026, 8:00:01 PM)

After market: 36.64 0 (0%)

36.64

+0.92 (+2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners85.11%
Inst Owner Change6.21%
Ins Owners2.59%
Ins Owner Change-4.81%
Market Cap665.02M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (30.84%)
Short Float %21.09%
Short Ratio8.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)3.68%
PT rev (3m)22.61%
EPS NQ rev (1m)17.09%
EPS NQ rev (3m)32.38%
EPS NY rev (1m)0.92%
EPS NY rev (3m)19.02%
Revenue NQ rev (1m)3.4%
Revenue NQ rev (3m)4.28%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 5.94
Fwd PE 9.48
P/S 2.36
P/FCF 9.76
P/OCF 9.75
P/B 5.65
P/tB 7.21
EV/EBITDA 4.11
EPS(TTM)6.17
EY16.84%
EPS(NY)3.87
Fwd EY10.55%
FCF(TTM)3.75
FCFY10.25%
OCF(TTM)3.76
OCFY10.25%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -0.88
F-Score7
WACC8.91%
ROIC/WACC7.12
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y38.7%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.91%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.